Previous 10 | Next 10 |
2023-04-18 10:04:36 ET Gainers: Dermata Therapeutics ( DRMA ) +108% . BELLUS Health ( BLU ) +99% . Allarity Therapeutics ( ALLR ) +69% . Gamida Cell ( GMDA ) +37% . YS Biopharma ( YS ) +28% . Losers: China Jo-Jo Drugs...
2023-04-17 10:02:16 ET Gainers: Prometheus Biosciences ( RXDX ) +69% . CNS Pharmaceuticals ( CNSP ) +53% . Revelation Biosciences ( REVB ) +29% . Windtree Therapeutics ( WINT ) +26% . Kiromic BioPharma ( KRBP ) +22% . Loser...
CAMBRIDGE, MA / ACCESSWIRE / April 17, 2023 / Allarity Therapeutics (NASDAQ:ALLR) dosed its first patient in Phase 1b of its clinical trial for the novel combination therapy of two drugs, stenoparib and dovitinib. The company is evaluating the safety, dosing, and potential therapeutic benefi...
2023-04-14 13:00:16 ET Gainers: SAI.TECH Global Corporation ( SAI ) +166% . CXApp ( CXAI ) +80% . Oblong ( OBLG ) +88% . Allarity Therapeutics ( ALLR ) +57% . Marpai ( MRAI ) +33% . Eightco Holdings ( OCTO ) +34% . ...
FOR IMMEDIATE RELEASE Abstract Evaluating Allarity’s DRP ® Companion Diagnostic for Cisplatin Accepted at 2023 ASCO Annual Meeting Poster presentation focused on a Phase 2 Clinical Study Evaluating the Utility of a DRP ® Companion Dia...
2023-04-06 10:02:19 ET Gainers: Bullfrog AI ( BFRG ) +16% . HUTCHMED (China) ( HCM ) +10% . Aprea Therapeutics ( APRE ) +8% . Clearside Biomedical ( CLSD ) +5% . Soleno Therapeutics ( SLNO ) +5% . Losers: Scilex ( SCLX ...
2023-03-29 08:23:45 ET Draganfly DPRO -17% on proposed securities offering . SomaLogic SLGC -15% on Q4 earnings release . Shift Technologies SFT -15% on Q4 earnings release . Sharecare SHCR -12% on Q4 earnings release . Allarity Therapeu...
2023-03-28 10:00:38 ET Gainers: Biomea Fusion ( BMEA ) +56% . Oscar Health ( OSCR ) +54% . Viking Therapeutics ( VKTX ) +51% . Intra-Cellular Therapies ( ITCI ) +20% . Guardion Health Sciences ( GHSI ) +17% . Losers...
2023-03-28 08:31:04 ET Monopar Therapeutics MNPR -50% as Validive program gets axed after trial failure . WiSA Technologies WISA -28% after proposes securities offering . OncoSec Medical ( ONCS ) -25% . Allarity Therapeutics ALLR -18% amid enr...
2023-03-28 07:06:22 ET Allarity Therapeutics ( NASDAQ: ALLR ) said it is working towards accelerating patient recruitment in ongoing phase 2 trials of Ixempra and stenoparib as monotherapies for cancer. The company expects interim data readouts by the end of 2023. H...
News, Short Squeeze, Breakout and More Instantly...
Trending Stock
7.99%Change Percent:
Allarity Therapeutics Inc. Company Name:
ALLR Stock Symbol:
NASDAQ Market:
Allarity Therapeutics Inc. Website:
A look at the top 10 most actives in the United States Sangamo Therapeutics Inc. (SGMO) rose 50.7% to $0.604699 on volume of 90,844,210 shares Selina Hospitality PLC (SLNA) rose 7.7% to $0.028 on volume of 57,431,570 shares NuZee Inc. (NUZE) rose 260.1% to $3.7094 on volume of 53,639,595 ...
Boston (July 24, 2024)—Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing personalized cancer treatments, encourages its stockholders to participate actively in the ...
Current Cash Balance of $20 million Expected to Provide Runway Into 2026 Allarity to Pause Use of ATM Cap Table Successfully Cleaned Up Allarity’s Stenoparib Shows Extended Duration of Phase 2 Clinical Benefit Boston (July 22, 2024)—Allarity The...